Fatty Acid Oxidation-Driven Src Links Mitochondrial Energy Reprogramming and Oncogenic Properties in Triple-Negative Breast Cancer

Cell Reports

Volumn 14, Issue 9, 2016, Pages 2154-2165

  Park, Jun Hyoung ^a   Vithayathil, Sajna ^a   Kumar, Santosh ^a   Sung, Pi Lin ^a,b   Dobrolecki, Lacey Elizabeth ^a   Putluri, Vasanta ^a   Bhat, Vadiraja B ^c   Bhowmik, Salil Kumar ^a   Gupta, Vineet ^a   Arora, Kavisha ^a   Wu, Danli ^d   Tsouko, Efrosini ^e   Zhang, Yiqun ^a   Maity, Suman ^a   Donti, Taraka R ^a   Graham, Brett H ^a   Frigo, Daniel E ^e,f   Coarfa, Cristian ^a   Yotnda, Patricia ^d   Putluri, Nagireddy ^a   Sreekumar, Arun ^a   Lewis, Michael T ^a   Creighton, Chad J ^a   Wong, Lee Jun C ^a   Kaipparettu, Benny Abraham ^a   more..

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c AGILENT TECHNOLOGIES   (United States)

^d CENTER FOR CELL AND GENE THERAPY   (United States)

^e University of Houston   (United States)

^f HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARNITINE PALMITOYLTRANSFERASE; CARNITINE PALMITOYLTRANSFERASE 1A; CARNITINE PALMITOYLTRANSFERASE 2; MITOCHONDRIAL DNA; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; FATTY ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHOSPHORYLATION; BREAST CANCER CELL LINE; CONTROLLED STUDY; CPT1A GENE; CPT2 GENE; ENERGY METABOLISM; FATTY ACID OXIDATION; FEMALE; METASTASIS; MOUSE; NONHUMAN; NUCLEAR REPROGRAMMING; ONCOGENE; ONCOGENE SRC; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; TRIPLE NEGATIVE BREAST CANCER; ANIMAL; CANCER TRANSPLANTATION; CARCINOGENESIS; HUMAN; METABOLISM; MITOCHONDRION; OXIDATION REDUCTION REACTION; PATHOLOGY; PHOSPHORYLATION; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; CARCINOGENESIS; CELL LINE, TUMOR; ENERGY METABOLISM; FATTY ACIDS; FEMALE; HUMANS; MICE, SCID; MITOCHONDRIA; NEOPLASM TRANSPLANTATION; OXIDATION-REDUCTION; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; SRC-FAMILY KINASES; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84960423377     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2016.02.004     Document Type: Article

References (66)

1. Acín-Perez R., Salazar E., Brosel S., Yang H., Schon E.A., Manfredi G. Modulation of mitochondrial protein phosphorylation by soluble adenylyl cyclase ameliorates cytochrome oxidase defects. EMBO Mol. Med. 2009, 1:392-406.
2. Acín-Pérez R., Carrascoso I., Baixauli F., Roche-Molina M., Latorre-Pellicer A., Fernández-Silva P., Mittelbrunn M., Sanchez-Madrid F., Pérez-Martos A., Lowell C.A., et al. ROS-triggered phosphorylation of complex II by Fgr kinase regulates cellular adaptation to fuel use. Cell Metab. 2014, 19:1020-1033.
3. Aleshin A., Finn R.S. SRC: a century of science brought to the clinic. Neoplasia 2010, 12:599-607.
4. Anbalagan M., Moroz K., Ali A., Carrier L., Glodowski S., Rowan B.G. Subcellular localization of total and activated Src kinase in African American and Caucasian breast cancer. PLoS ONE 2012, 7:e33017.
5. Balaban S., Lee L.S., Schreuder M., Hoy A.J. Obesity and cancer progression: is there a role of fatty acid metabolism?. BioMed Res. Int. 2015, 2015:274585.
6. Basak N.P., Banerjee S. Mitochondrial dependency in progression of acute myeloid leukemia. Mitochondrion 2015, 21:41-48.
7. Biswas S., Lunec J., Bartlett K. Non-glucose metabolism in cancer cells--is it all in the fat?. Cancer Metastasis Rev. 2012, 31:689-698.
8. Caino M.C., Ghosh J.C., Chae Y.C., Vaira V., Rivadeneira D.B., Faversani A., Rampini P., Kossenkov A.V., Aird K.M., Zhang R., et al. PI3K therapy reprograms mitochondrial trafficking to fuel tumor cell invasion. Proc. Natl. Acad. Sci. USA 2015, 112:8638-8643.
9. Cantor J.R., Sabatini D.M. Cancer cell metabolism: one hallmark, many faces. Cancer Discov. 2012, 2:881-898.
10. Carracedo A., Cantley L.C., Pandolfi P.P. Cancer metabolism: fatty acid oxidation in the limelight. Nat. Rev. Cancer 2013, 13:227-232.
11. Chlebowski R.T., Blackburn G.L. Abstract S5-08: Final survival analysis from the randomized Women's Intervention Nutrition Study (WINS) evaluating dietary intervention as adjuvant breast cancer therapy. Cancer Res. 2015, 75:S5-S08.
12. Constance J.E., Lim C.S. Targeting malignant mitochondria with therapeutic peptides. Ther. Deliv. 2012, 3:961-979.
13. Costantini P., Jacotot E., Decaudin D., Kroemer G. Mitochondrion as a novel target of anticancer chemotherapy. J. Natl. Cancer Inst. 2000, 92:1042-1053.
14. Creighton C.J. Multiple oncogenic pathway signatures show coordinate expression patterns in human prostate tumors. PLoS ONE 2008, 3:e1816.
15. Erol A. Retrograde regulation due to mitochondrial dysfunction may be an important mechanism for carcinogenesis. Med. Hypotheses 2005, 65:525-529.
16. Finn R.S. Targeting Src in breast cancer. Ann. Oncol. 2008, 19:1379-1386.
17. Finn R.S., Bengala C., Ibrahim N., Roché H., Sparano J., Strauss L.C., Fairchild J., Sy O., Goldstein L.J. Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study. Clin. Cancer Res. 2011, 17:6905-6913.
18. Ghosh J.C., Siegelin M.D., Vaira V., Faversani A., Tavecchio M., Chae Y.C., Lisanti S., Rampini P., Giroda M., Caino M.C., et al. Adaptive mitochondrial reprogramming and resistance to PI3K therapy. J. Natl. Cancer Inst. 2015, 107:107.
19. Gucalp A., Sparano J.A., Caravelli J., Santamauro J., Patil S., Abbruzzi A., Pellegrino C., Bromberg J., Dang C., Theodoulou M., et al. Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer. Clin. Breast Cancer 2011, 11:306-311.
20. Hail N. Mitochondria: A novel target for the chemoprevention of cancer. Apoptosis 2005, 10:687-705.
21. Harjes U., Kalucka J., Carmeliet P. Targeting fatty acid metabolism in cancer and endothelial cells. Crit. Rev. Oncol. Hematol. 2016, 97:15-21.
22. Hebert-Chatelain E. Src kinases are important regulators of mitochondrial functions. Int. J. Biochem. Cell Biol. 2013, 45:90-98.
23. Herold C.I., Chadaram V., Peterson B.L., Marcom P.K., Hopkins J., Kimmick G.G., Favaro J., Hamilton E., Welch R.A., Bacus S., Blackwell K.L. Phase II trial of dasatinib in patients with metastatic breast cancer using real-time pharmacodynamic tissue biomarkers of Src inhibition to escalate dosing. Clin. Cancer Res. 2011, 17:6061-6070.
24. Hoy M.K., Winters B.L., Chlebowski R.T., Papoutsakis C., Shapiro A., Lubin M.P., Thomson C.A., Grosvenor M.B., Copeland T., Falk E., et al. Implementing a low-fat eating plan in the Women's Intervention Nutrition Study. J. Am. Diet. Assoc. 2009, 109:688-696.
25. Ishikawa K., Takenaga K., Akimoto M., Koshikawa N., Yamaguchi A., Imanishi H., Nakada K., Honma Y., Hayashi J. ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science 2008, 320:661-664.
26. Kaipparettu B.A., Ma Y., Wong L.J. Functional effects of cancer mitochondria on energy metabolism and tumorigenesis: utility of transmitochondrial cybrids. Ann. N Y Acad. Sci. 2010, 1201:137-146.
27. Kaipparettu B.A., Ma Y., Park J.H., Lee T.L., Zhang Y., Yotnda P., Creighton C.J., Chan W.Y., Wong L.J. Crosstalk from non-cancerous mitochondria can inhibit tumor properties of metastatic cells by suppressing oncogenic pathways. PLoS ONE 2013, 8:e61747.
28. Kessler J.D., Kahle K.T., Sun T., Meerbrey K.L., Schlabach M.R., Schmitt E.M., Skinner S.O., Xu Q., Li M.Z., Hartman Z.C., et al. A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science 2012, 335:348-353.
29. King M.P., Attardi G. Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. Science 1989, 246:500-503.
30. LeBleu V.S., O'Connell J.T., Gonzalez Herrera K.N., Wikman H., Pantel K., Haigis M.C., de Carvalho F.M., Damascena A., Domingos Chinen L.T., Rocha R.M., et al. PGC-1α mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat. Cell Biol. 2014, 16:992-1003. 1-15.
31. Li J.L., Wang Q.Y., Luan H.Y., Kang Z.C., Wang C.B. Effects of L-carnitine against oxidative stress in human hepatocytes: involvement of peroxisome proliferator-activated receptor alpha. J. Biomed. Sci. 2012, 19:32.
32. Liu J., Cho S.N., Akkanti B., Jin N., Mao J., Long W., Chen T., Zhang Y., Tang X., Wistub I.I., et al. ErbB2 pathway activation upon smad4 loss promotes lung tumor growth and metastasis. Cell Rep. 2015, S2211-1247(15)00142-4. 10.1016/j.celrep.2015.02.014.
33. Lorincz A.M., Sukumar S. Molecular links between obesity and breast cancer. Endocr. Relat. Cancer 2006, 13:279-292.
34. Lu C.L., Qin L., Liu H.C., Candas D., Fan M., Li J.J. Tumor cells switch to mitochondrial oxidative phosphorylation under radiation via mTOR-mediated hexokinase II inhibition--a Warburg-reversing effect. PLoS ONE 2015, 10:e0121046.
35. Maiuri M.C., Kroemer G. Essential role for oxidative phosphorylation in cancer progression. Cell Metab. 2015, 21:11-12.
36. Mayer E.L., Krop I.E. Advances in targeting SRC in the treatment of breast cancer and other solid malignancies. Clin. Cancer Res. 2010, 16:3526-3532.
37. Mescka C., Moraes T., Rosa A., Mazzola P., Piccoli B., Jacques C., Dalazen G., Coelho J., Cortes M., Terra M., et al. In vivo neuroprotective effect of L-carnitine against oxidative stress in maple syrup urine disease. Metab. Brain Dis. 2011, 26:21-28.
38. Miyazaki T., Neff L., Tanaka S., Horne W.C., Baron R. Regulation of cytochrome c oxidase activity by c-Src in osteoclasts. J. Cell Biol. 2003, 160:709-718.
39. Neuzil J., Dong L.F., Rohlena J., Truksa J., Ralph S.J. Classification of mitocans, anti-cancer drugs acting on mitochondria. Mitochondrion 2013, 13:199-208.
40. Ni Chonghaile T., Sarosiek K.A., Vo T.T., Ryan J.A., Tammareddi A., Moore Vdel.G., Deng J., Anderson K.C., Richardson P., Tai Y.T., et al. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science 2011, 334:1129-1133.
41. O'Rourke B., Van Eyk J.E., Foster D.B. Mitochondrial protein phosphorylation as a regulatory modality: implications for mitochondrial dysfunction in heart failure. Congest. Heart Fail. 2011, 17:269-282.
42. Ogura M., Yamaki J., Homma M.K., Homma Y. Mitochondrial c-Src regulates cell survival through phosphorylation of respiratory chain components. Biochem. J. 2012, 447:281-289.
43. Ogura M., Yamaki J., Homma M.K., Homma Y. Phosphorylation of flotillin-1 by mitochondrial c-Src is required to prevent the production of reactive oxygen species. FEBS Lett. 2014, 588:2837-2843.
44. Ohsawa S., Sato Y., Enomoto M., Nakamura M., Betsumiya A., Igaki T. Mitochondrial defect drives non-autonomous tumour progression through Hippo signalling in Drosophila. Nature 2012, 490:547-551.
45. Oneyama C., Okada M. MicroRNAs as the fine-tuners of Src oncogenic signalling. J. Biochem. 2015, 157:431-438.
46. Pal S.K., Mortimer J. Triple-negative breast cancer: novel therapies and new directions. Maturitas 2009, 63:269-274.
47. Pierobon M., Frankenfeld C.L. Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis. Breast Cancer Res. Treat. 2013, 137:307-314.
48. Ribas G.S., Vargas C.R., Wajner M. L-carnitine supplementation as a potential antioxidant therapy for inherited neurometabolic disorders. Gene 2014, 533:469-476.
49. Roberts D.L., Dive C., Renehan A.G. Biological mechanisms linking obesity and cancer risk: new perspectives. Annu. Rev. Med. 2010, 61:301-316.
50. Roskoski R. Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors. Pharmacol. Res. 2015, 94:9-25.
51. Salvi M., Brunati A.M., Bordin L., La Rocca N., Clari G., Toninello A. Characterization and location of Src-dependent tyrosine phosphorylation in rat brain mitochondria. Biochim. Biophys. Acta 2002, 1589:181-195.
52. Samudio I., Harmancey R., Fiegl M., Kantarjian H., Konopleva M., Korchin B., Kaluarachchi K., Bornmann W., Duvvuri S., Taegtmeyer H., Andreeff M. Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J. Clin. Invest. 2010, 120:142-156.
53. Setoyama D., Fujimura Y., Miura D. Metabolomics reveals that carnitine palmitoyltransferase-1 is a novel target for oxidative inactivation in human cells. Genes Cells 2013, 18:1107-1119.
54. Sirvent A., Urbach S., Roche S. Contribution of phosphoproteomics in understanding SRC signaling in normal and tumor cells. Proteomics 2015, 15:232-244.
55. Tan A.S., Baty J.W., Dong L.F., Bezawork-Geleta A., Endaya B., Goodwin J., Bajzikova M., Kovarova J., Peterka M., Yan B., et al. Mitochondrial genome acquisition restores respiratory function and tumorigenic potential of cancer cells without mitochondrial DNA. Cell Metab. 2015, 21:81-94.
56. Tibaldi E., Brunati A.M., Massimino M.L., Stringaro A., Colone M., Agostinelli E., Arancia G., Toninello A. Src-Tyrosine kinases are major agents in mitochondrial tyrosine phosphorylation. J. Cell. Biochem. 2008, 104:840-849.
57. Tryfonopoulos D., Walsh S., Collins D.M., Flanagan L., Quinn C., Corkery B., McDermott E.W., Evoy D., Pierce A., O'Donovan N., et al. Src: a potential target for the treatment of triple-negative breast cancer. Ann. Oncol. 2011, 22:2234-2240.
58. Turkoz F.P., Solak M., Petekkaya I., Keskin O., Kertmen N., Sarici F., Arik Z., Babacan T., Ozisik Y., Altundag K. The prognostic impact of obesity on molecular subtypes of breast cancer in premenopausal women. J. BUON 2013, 18:335-341.
59. Vahedi S., Chueh F.Y., Chandran B., Yu C.L. Lymphocyte-specific protein tyrosine kinase (Lck) interacts with CR6-interacting factor 1 (CRIF1) in mitochondria to repress oxidative phosphorylation. BMC Cancer 2015, 15:551.
60. Viale A., Corti D., Draetta G.F. Tumors and mitochondrial respiration: a neglected connection. Cancer Res. 2015, 75:3685-3686.
61. Villanueva M.T. Metabolism: the mitochondria thief. Nat. Rev. Cancer 2015, 15:70-71.
62. Vithayathil S.A., Ma Y., Kaipparettu B.A. Transmitochondrial cybrids: tools for functional studies of mutant mitochondria. Methods Mol. Biol. 2012, 837:219-230.
63. Ward P.S., Thompson C.B. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 2012, 21:297-308.
64. Xu Q., Biener-Ramanujan E., Yang W., Ramanujan V.K. Targeting metabolic plasticity in breast cancer cells via mitochondrial complex I modulation. Breast Cancer Res. Treat. 2015, 150:43-56.
65. Zhang S., Yu D. Targeting Src family kinases in anti-cancer therapies: turning promise into triumph. Trends Pharmacol. Sci. 2012, 33:122-128.
66. Zhang X., Claerhout S., Prat A., Dobrolecki L.E., Petrovic I., Lai Q., Landis M.D., Wiechmann L., Schiff R., Giuliano M., et al. A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res. 2013, 73:4885-4897.